Loading: 100%
AKORN INC logo
no logo available
General Information
Investor relations pageIR page no data available
Founding year no data available
Headquarter , , no data available
Employees (as per )no data available
Sector Drug Manufacturers, HealthcareDrug Manufacturers, Healthcareno data available
Ticker AKRXno data available
Financial year endsFY ends End of Decemberno data available
Stock Information (historical prices adjusted for splits and dividends)
Adj. Closing prices (in USD) -Common sharesNov. 16Jan. 17März 17Mai 17Juli 17Sep. 171520253035
datesClosing price (adj.)
13.10.201733.22
11.10.201732.95
04.10.201732.90
27.09.201733.15
20.09.201733.15
13.09.201733.15
06.09.201732.96
30.08.201732.83
23.08.201732.32
16.08.201733.30
09.08.201733.36
02.08.201733.48
26.07.201733.63
19.07.201733.64
12.07.201733.55
05.07.201733.51
27.06.201733.41
20.06.201733.41
13.06.201733.44
06.06.201733.23
30.05.201733.20
23.05.201733.18
16.05.201733.27
09.05.201733.27
02.05.201733.50
25.04.201733.09
18.04.201733.04
11.04.201732.76
04.04.201723.33
28.03.201724.77
21.03.201722.37
14.03.201722.22
07.03.201722.48
28.02.201720.81
21.02.201721.91
14.02.201721.65
07.02.201719.84
31.01.201719.10
24.01.201719.77
17.01.201721.25
10.01.201722.54
03.01.201722.07
27.12.201621.48
19.12.201621.05
12.12.201620.21
05.12.201620.22
28.11.201622.40
21.11.201621.79
14.11.201622.96
07.11.201620.26
31.10.201623.95
24.10.201626.23
17.10.201626.53
no share price data source found
Share price data requested
Key Figures
Last Closing Price
as per Oct 13, 2017, in USD
33.22n/a
Market Capitalisation
in million USD
4,138n/a
Enterprise Value
in million USD
4,640n/a
Common Shares Outstanding
as per Apr 28, 2017
124,555,268n/a
Preferred Shares Outstanding
as per Apr 28, 2017
n/a
Average Basic Shares Outstanding
TTM
124,095,250n/a
Average Diluted Shares Outstanding
TTM
125,562,250n/a
Index Membership
n/a
Business Summary
Akorn Inc is a United States based generic pharmaceutical company. It develops, manufactures and markets generic and branded prescription pharmaceuticals as well as private-label over-the-counter consumer health products and animal health pharmaceuticals.
no data available
Key Financials & Ratios (all figures TTM as per Mar 31, 2017, million USD, full statements further below)
Profit & Loss
Revenues 1,102n/a
Gross Profit 660n/a
Operating Income 355n/a
EBITDA 442n/a
Net Profit 183n/a
Balance Sheet
Cash and Cash Equivalents 309n/a
Receivables 234n/a
Total Current Assets 736n/a
PP&E 253n/a
Total Assets 2,026n/a
Accounts Payable 51n/a
Current Debt 0n/a
Total Current Liabilities 175n/a
Long-Term Debt 811n/a
Total Liabilities 1,155n/a
Total Equity 870n/a
Cash Flow
Depreciation & Amortisation 86n/a
Change in Working Capital -20n/a
Operating Cash Flow 286n/a
Net Change in PP&E and Intangibles -84n/a
Investing Cash Flow -84n/a
Dividends Paid 0n/a
Financing Cash Flow -36n/a
Total Change in Cash 166n/a
Free Cash Flow 250n/a
Profitability Ratios
Gross Margin 59.9%n/a
Operating Margin 32.3%n/a
Net Profit Margin 16.6%n/a
Return on Equity 21.1%n/a
Return on Assets 9.0%n/a
Per Share Figures
Basic EPS 1.48n/a
Diluted EPS 1.46n/a
Sales per Share 8.88n/a
Book Value per Share 7.01n/a
FCF per Share 2.02n/a
Dividends per Share 0.00n/a
Price Multiples
Price to Earnings Ratio 22.48n/a
Price to Sales Ratio 3.74n/a
Price to Book Value 4.74n/a
Price to Free Cash Flow 16.46n/a
Valuation Metrics
EV/EBITDA 10.50n/a
EV/Sales 4.21n/a
Book to Market Value 0.21n/a
Other Ratios
Current Ratio 420.9%n/a
Liabilities to Equity Ratio 132.7%n/a
Debt to Assets Ratio 40.1%n/a
Profit & Loss StatementP&L data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Revenue
76
86
137
256
318
555
985
1,117
Sales & Services Revenue
0
0
0
0
0
0
0
0
Financing Revenue
0
0
0
0
0
0
0
0
Other Revenue
0
0
0
0
0
0
0
0
Cost of revenue
-60
-44
-57
-107
-146
-294
-389
-443
Cost of Goods & Services
0
0
0
0
0
0
0
0
Cost of Financing Revenue
0
0
0
0
0
0
0
0
Cost of Other Revenue
0
0
0
0
0
0
0
0
Gross Profit
16
42
80
149
172
261
596
674
Other Operating Income
0
0
0
0
0
0
0
0
Operating Expenses
-29
-31
-46
-71
-81
-168
-269
-306
Selling, General & Administrative
-23
-23
-32
-48
-54
-93
-162
-198
Selling & Marketing
0
0
0
0
0
0
0
0
General & Administrative
0
0
0
0
0
0
0
0
Research & Development
-5
-7
-12
-16
-20
-31
-41
-43
Depreciation & Amortization
-2
-1
-2
-7
-7
-43
-66
-66
Provision For Doubtful Accounts
0
0
0
0
0
0
0
0
Other Operating Expense
0
0
0
0
0
0
0
0
Operating Income (Loss)
-14
11
34
78
91
94
327
368
Non-Operating Income (Loss)
-2
-1
-5
-10
-8
-35
-59
-45
Interest Expense, net
-2
-1
-4
-10
-9
-36
-52
-43
Interest Expense
0
0
0
0
0
0
0
0
Interest Income
0
0
0
0
0
0
0
0
Other Investment Income (Loss)
0
0
0
0
0
0
0
0
Foreign Exchange Gain (Loss)
0
0
0
0
0
0
0
0
Income (Loss) from Affiliates
0
0
0
0
0
0
0
0
Other Non-Operating Income (Loss)
0
0
0
0
0
1
-7
-3
Pretax Income (Loss), Adjusted
-15
10
29
67
83
59
268
323
Abnormal Gains (Losses)
-10
12
12
-10
0
-34
-36
-52
Acquired In-Process R&D
0
0
0
0
0
0
0
0
Merger / Acquisition Expense
0
0
0
0
0
0
0
0
Abnormal Derivatives
0
0
0
0
0
0
0
0
Disposal of Assets
0
0
0
0
0
0
0
0
Early extinguishment of Debt
0
0
0
0
0
0
0
0
Asset Write-Down
0
0
0
0
0
0
0
0
Impairment of Goodwill & Intangibles
0
0
0
0
0
0
0
0
Sale of Business
0
0
0
0
0
0
0
0
Legal Settlement
0
0
0
0
0
0
0
0
Restructuring Charges
0
0
0
0
0
0
0
0
Sale of and Unrealized Investments
0
0
0
0
0
0
0
0
Insurance Settlement
0
0
0
0
0
0
0
0
Other Abnormal Items
0
0
0
0
0
0
0
0
Pretax Income (Loss)
-25
22
41
58
83
25
232
271
Income Tax (Expense) Benefit, net
0
0
2
-22
-31
-11
-81
-87
Current Income Tax
0
0
0
0
0
0
0
0
Deferred Income Tax
0
0
0
0
0
0
0
0
Tax Allowance/Credit
0
0
0
0
0
0
0
0
Income (Loss) from Affiliates, net of taxes
0
0
0
0
0
0
0
0
Income (Loss) from Continuing Operations
-25
22
43
35
52
14
151
184
Net Extraordinary Gains (Losses)
0
0
0
0
0
-1
0
0
Discontinued Operations
0
0
0
0
0
-1
0
0
XO & Accounting Charges & Other
0
0
0
0
0
0
0
0
Income (Loss) Including Minority Interest
-25
22
43
35
52
14
151
184
Minority Interest
0
0
0
0
0
0
0
0
Net Income
-25
22
43
35
52
14
151
184
Preferred Dividends
0
0
0
0
0
0
0
0
Other Adjustments
0
0
0
0
0
0
0
0
Net Income Available to Common Shareholders
-25
22
43
35
52
14
151
184
Remarks
restated on Mar 15, 2012 n/a
calculated values,
restated on Mar 1, 2013 n/a
calculated values,
restated on Mar 14, 2014 n/a
calculated values,
restated on Mar 17, 2015 n/a
calculated values,
restated on May 10, 2016 n/a
calculated values,
restated on Mar 1, 2017 n/a
calculated values,
restated on Mar 1, 2017 n/a
calculated values,
restated on Mar 1, 2017 n/a
calculated values,
Balance SheetBS data quality: 80% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Assets
Cash, Cash Equivalents & Short Term Investments
n/a
42
84
41
34
78
352
202
Cash & Cash Equivalents
n/a
42
84
41
34
71
346
201
Short Term Investments
n/a
0
0
0
0
7
6
1
Accounts & Notes Receivable
n/a
11
25
51
65
188
151
283
Accounts Receivable, Net
n/a
11
25
51
65
188
151
283
Notes Receivable, Net
n/a
0
0
0
0
0
0
0
Unbilled Revenues
n/a
0
0
0
0
0
0
0
Inventories
n/a
19
35
52
56
135
185
175
Raw Materials
n/a
0
0
0
0
0
0
0
Work In Process
n/a
0
0
0
0
0
0
0
Finished Goods
n/a
0
0
0
0
0
0
0
Other Inventory
n/a
0
0
0
0
0
0
0
Other Short Term Assets
n/a
2
11
14
14
75
20
26
Prepaid Expenses
n/a
2
3
5
6
37
20
26
Derivative & Hedging Assets
n/a
0
0
0
0
0
0
0
Assets Held-for-Sale
n/a
0
0
0
0
0
0
0
Deferred Tax Assets
n/a
0
8
9
8
38
0
0
Income Taxes Receivable
n/a
0
0
0
0
0
0
0
Discontinued Operations
n/a
0
0
0
0
0
0
0
Miscellaneous Short Term Assets
n/a
0
0
0
0
0
0
0
Total Current Assets
n/a
74
156
159
169
476
708
686
Property, Plant & Equipment, Net
n/a
33
44
81
82
144
180
238
Property, Plant & Equipment
n/a
0
0
0
0
0
0
0
Accumulated Depreciation
n/a
0
0
0
0
0
0
0
Long Term Investments & Receivables
n/a
0
10
10
10
0
0
0
Long Term Investments
n/a
0
0
0
0
0
0
0
Long Term Marketable Securities
n/a
0
0
0
0
0
0
0
Long Term Receivables
n/a
0
0
0
0
0
0
0
Other Long Term Assets
n/a
6
97
120
171
1,273
1,155
1,050
Intangible Assets
n/a
0
0
0
0
0
0
0
Goodwill
n/a
0
12
32
30
285
285
284
Other Intangible Assets
n/a
0
13
17
15
256
0
0
Prepaid Expense
n/a
0
0
0
0
0
0
0
Deferred Tax Assets
n/a
0
0
1
2
2
4
5
Derivative & Hedging Assets
n/a
0
0
0
0
0
0
0
Prepaid Pension Costs
n/a
0
0
0
0
0
0
0
Discontinued Operations
n/a
0
0
0
0
0
0
0
Investments in Affiliates
n/a
0
0
0
0
0
0
0
Miscellaneous Long Term Assets
n/a
6
72
70
125
730
866
760
Total Noncurrent Assets
n/a
39
151
211
263
1,418
1,334
1,288
Total Assets
n/a
112
307
370
432
1,894
2,043
1,974
Liabilities and owners' equity
Payables & Accruals
n/a
12 11763000
28 28289000
43 43291000
47 46517000
129 129434000
174 173630000
171 170561000
Accounts Payable
n/a
5 4894000
18 17874000
22 21784000
23 22999000
47 47317000
46 46019000
60 59534000
Accrued Taxes
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Interest & Dividends Payable
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Other Payables & Accruals
n/a
7 6869000
10 10415000
22 21507000
24 23518000
82 82117000
128 127611000
111 111027000
Short Term Debt
n/a
0 0
0 0
0 0
0 0
10 10450000
53 52779000
0 0
Short Term Borrowings
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Short Term Capital Leases
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Current Portion of Long Term Debt
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Other Short Term Liabilities
n/a
11 11476000
19 18882000
19 19403000
15 14728000
11 10970000
5 4967000
5 4994000
Deferred Revenue
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Derivatives & Hedging
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Tax Liabilities
n/a
0 0
4 3742000
2 1991000
0 0
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Miscellaneous Short Term Liabilities
n/a
11 11476000
15 15140000
17 17412000
15 14728000
11 10970000
5 4967000
5 4994000
Total Current Liabilities
n/a
23 23239000
47 47171000
63 62694000
61 61245000
151 150854000
231 231376000
176 175555000
Long Term Debt
n/a
0 0
101 100808000
105 104637000
109 108750000
1,114 1114481000
994 994033000
810 809979000
Long Term Borrowings
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Long Term Capital Leases
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Other Long Term Liabilities
n/a
20 19673000
19 18904000
19 19099000
20 19576000
272 272264000
196 195571000
169 169002000
Accrued Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Pension Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Pensions
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Other Post-Retirement Benefits
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Compensation
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Revenue
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Tax Liabilities
n/a
0 0
0 0
0 0
0 0
269 269428000
189 188808000
158 157607000
Derivatives & Hedging
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Miscellaneous Long Term Liabilities
n/a
20 19673000
19 18904000
19 19099000
20 19576000
3 2836000
7 6763000
11 11395000
Total Noncurrent Liabilities
n/a
20 19673000
120 119712000
124 123736000
128 128326000
1,387 1386745000
1,190 1189604000
979 978981000
Total Liabilities
n/a
43 42912000
167 166883000
186 186430000
190 189571000
1,538 1537599000
1,421 1420980000
1,155 1154536000
Preferred Equity
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Share Capital & Additional Paid-In Capital
n/a
182 182466000
213 212636000
226 226035000
239 239235000
342 342252000
459 458659000
522 521860000
Common Stock
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Additional Paid in Capital
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Other Share Capital
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Treasury Stock
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Retained Earnings
n/a
-115 -115387000
-72 -72374000
-37 -36996000
15 15366000
29 29250000
180 180048000
319 319291000
Other Equity
n/a
0 0
0 0
-6 -5904000
-12 -12367000
-15 -15195000
-17 -17142000
-22 -21967000
Equity Before Minority Interest
n/a
67 67079000
140 140262000
183 183135000
242 242234000
356 356307000
622 621565000
819 819184000
Minority Interest
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Total Equity
n/a
67 67079000
140 140262000
183 183135000
242 242234000
356 356307000
622 621565000
819 819184000
Total Liabilities & Equity
n/a
110 109991000
307 307145000
370 369565000
432 431805000
1,894 1893906000
2,043 2042545000
1,974 1973720000
Remarks restated on n/a restated on Mar 15, 2012 n/a restated on Mar 1, 2013 n/a restated on Mar 14, 2014 n/a restated on May 10, 2016 n/a restated on Jun 2, 2016 n/a restated on Mar 1, 2017 n/a restated on May 4, 2017 n/a
Cash Flow StatementCF data quality: 97% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Net Income/Starting Line
-25
22
43
35
52
14
151
184
Net Income
0
0
0
0
0
0
0
0
Net Income From Discontinued Operations
0
0
0
0
0
0
0
0
Other Adjustments
0
0
0
0
0
0
0
0
Depreciation & Amortization
5
5
5
11
14
79
92
88
Non-Cash Items
8
-9
-10
9
5
-33
-40
34
Stock-Based Compensation
0
0
0
0
0
0
0
0
Deferred Income Taxes
0
0
0
0
0
0
0
0
Other Non-Cash Adjustments
0
0
0
0
0
0
0
0
Change in Working Capital
10
-4
-19
-30
-14
-20
96
-138
(Increase) Decrease in Accounts Receivable
0
0
0
0
0
0
0
0
(Increase) Decrease in Inventories
0
0
0
0
0
0
0
0
Increase (Decrease) in Accounts Payable
0
0
0
0
0
0
0
0
Increase (Decrease) in Other
0
0
0
0
0
0
0
0
Net Cash From Discontinued Operations (operating)
0
0
0
0
0
0
0
0
Cash from Operating Activities
-3
14
20
26
57
40
298
168
Change in Fixed Assets & Intangibles
-1
-5
-12
-20
-12
21
-29
-73
Disposition of Fixed Assets & Intangibles
0
0
0
0
0
0
0
0
Disposition of Fixed Assets
0
0
0
0
0
0
0
0
Disposition of Intangible Assets
0
0
0
0
0
0
0
0
Acquisition of Fixed Assets & Intangibles
0
0
0
0
0
0
0
0
Purchase of Fixed Assets
0
0
0
0
0
0
0
0
Acquisition of Intangible Assets
0
0
0
0
0
0
0
0
Other Change in Fixed Assets & Intangibles
0
0
0
0
0
0
0
0
Net Change in Long Term Investment
0
0
0
0
0
0
0
0
Decrease in Long Term Investment
0
0
0
0
0
0
0
0
Increase in Long Term Investment
0
0
0
0
0
0
0
0
Net Cash From Acquisitions & Divestitures
0
0
-87
-55
-55
-987
-24
0
Net Cash from Divestitures
0
0
0
0
0
0
0
0
Cash for Acqusition of Subsidiaries
0
0
0
0
0
0
0
0
Cash for Joint Ventures
0
0
0
0
0
0
0
0
Net Cash from Other Acquisitions
0
0
0
0
0
0
0
0
Other Investing Activities
2
35
4
0
0
0
0
0
Net Cash From Discontinued Operations (investing)
0
0
0
0
0
0
0
0
Cash from Investing Activities
0
30
-95
-76
-67
-967
-54
-73
Dividends Paid
0
0
0
0
0
0
0
0
Cash From (Repayment of) Debt
3
-9
120
0
0
960
-10
-200
Cash From (Repayment of) Short Term Debt, net
0
0
0
0
0
0
0
0
Cash From (Repayment of) Long Term Debt, net
0
0
0
0
0
0
0
0
Repayments of Long Term Debt
0
0
0
0
0
0
0
0
Cash From Long Term Debt
0
0
0
0
0
0
0
0
Cash From (Repurchase of) Equity
1
1
1
2
3
9
12
-35
Increase in Capital Stock
1
1
1
2
3
9
12
10
Decrease in Capital Stock
0
0
0
0
0
0
0
-45
Other Financing Activities
-1
5
-3
4
0
-6
30
-5
Net Cash From Discontinued Operations (financing)
0
0
0
0
0
0
0
0
Cash from Financing Activities
3
-4
118
6
3
963
32
-240
Net Cash Before Disc. Operations and FX
1
40
42
-43
-6
37
276
-145
Change in Cash from Disc. Operations and Other
0
0
0
0
0
0
0
0
Net Cash Before FX
1
40
42
-43
-6
37
276
-145
Effect of Foreign Exchange Rates
0
0
0
0
0
0
0
0
Net Changes in Cash
1
40
42
-43
-7
37
276
-145
Remarks
restated on Mar 15, 2012 n/a
calculated values,
restated on Mar 1, 2013 n/a
calculated values,
restated on Mar 14, 2014 n/a
calculated values,
restated on Mar 17, 2015 n/a
calculated values,
restated on May 10, 2016 n/a
calculated values,
restated on Mar 1, 2017 n/a
calculated values,
restated on Mar 1, 2017 n/a
calculated values,
restated on Mar 1, 2017 n/a
calculated values,
Some of the data shown on this page is provided for free by IEX
Sumo